Reviews of tizanidine and donepezil

Hospital Pharmacy

Volumn 32, Issue 8, 1997, Pages 1136-1156

  Levien, Terri ^b   Baker, Danial E ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ANTIHYPERTENSIVE AGENT; BACLOFEN; CENTRAL DEPRESSANT AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLONIDINE; DIAZEPAM; DONEPEZIL; ENZYME INHIBITOR; PHENYTOIN; TACRINE; TIZANIDINE;

ALZHEIMER DISEASE; ASTHENIA; CLINICAL TRIAL; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG MONITORING; DRUG POTENCY; DRUG RECEPTOR BINDING; FOOD DRUG INTERACTION; GASTROINTESTINAL SYMPTOM; HUMAN; MULTIPLE SCLEROSIS; NEUROTOXICITY; NONHUMAN; ORAL DRUG ADMINISTRATION; REVIEW; SPASTICITY; SPINAL CORD INJURY;

EID: 0030852995     PISSN: 00185787     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (37)

1. Zanaflex product literature. Athena Neurosciences, Inc.; December 10, 1996.
2. Reynolds JEF (ed). Martindale: The Extra Pharmacopoeia (CD-ROM Version). MICROMEDEX, INC.; 1994.
3. Koyuncuoglu H, et al. Effects of tizanidine on morphine physical dependence: Attenuation and intensification. Pharmacol Biochem Behav. 1992;42:693-698.
4. Meinck HM, et al. The stiff-man syndrome New pathophysiological aspects from abnormal exteroceptive reflexes and the response to clomipramine, clonidine, and tizanidine. J Neurol Neurosurg Psychiatry. 1984;47:280-287.
5. Fogelholm R, Murros K. Tizanidine in chronic tension-type headache: A placebo controlled double-blind cross-over study. Headache. 1992;32(10):509-513.
6. Leiphart JW, et al. A comparison of intrathecally administered narcotic and nonnarcotic analgesics for experimental chronic neuropathic pain. J Neurosurg. 1995;82:595-599.
7. Fromm GH, et al. A clinical and experimental investigation of the effects ot tizanidine in trigeminal neuralgia. Pain. 1995;53: 265-271.
8. Nakashima K, et al. Effects of tizanidine administration on exteroceptive suppression of the temporalis muscle in patients with chronic tension-type headache. Headache. 1994;34:455-457.
9. Nabeshima T, et al. Involvement of spinal and supraspinal structures in tizanidine-induced antinociceptive action. Neurosci Lett. 1986;63:1-4.
10. Tanabe M, et al. The pharmacological properties of CS-722, a newly synthesized centrally acting muscle relaxant. Neuropharmacology. 1992;31:1059-1066.
11. Turski L, et al. Substantia nigra and entopeduncular nucleus: Supraspinal sites of the muscle relaxant action of tizanidine. Brain Research. 1986;379:367-371.
12. Turski L, et al. Substantia nigra: A site of action of muscle relaxant drugs. Ann Neurol. 1990;28:341-348.
13. Coward DM, Tizanidine: Neuropharmacology and mechanism of action. Neurology. 1994;44(suppl 9):S6-S11.
14. Ono H, et al. Effects of tizanidine, a centrally acting muscle relaxant, on motor systems. Gen Pharmacol. 1986;17:137-142.
15. Milanov I, Georgicv D. Mechanisms of tizanidine action on spasticity. Acta Neurol Scand. 1994;89:274-279.
16. ten Houten R, et al. Spasmodic torticollis: Treatment with tizanidine. Acta Neurol Scand. 1984;70:373-376.
17. Lang AE, Riley DE. Tizanidine in cranial dystonia. Clin Neuropharmacol. 1992;15(2):142-147.
18. Muramatsu I, Kigoshi S. Tizanidine may discriminate between imidazoline-receptors and alpha2-adrenoceptors. Japan J Pharmacol. 1992;59:457-459.
19. Miettinen TJ, et al. The sedative and sympatholytic effects of oral tizanidine in healthy volunteers. Anesth Analg. 1996;82: 817-820.
20. Katz RT. Management of spasticity. Am J Phys Med Rehabil. 1988;67(3):108-116.
21. Kock P, et al. Biological fate of sirdalud in animals and man. Xenobiotica. 1989;19: 1255-1265.
22. Mathias CJ, et al. Pharmacodynamics and pharmacokinetics of the oral antispastic agent tizanidine in patients with spinal cord injury. J Rehabil Res Dev. 1989;26: 9-16.
23. Heazlewood V, et al. Tizanidine: Initial pharmacokinetic studies in patients with spasticity. Eur J Clin Pharmacol. 1983;25: 65-67.
24. Emre M, et al. Correlations between dose, plasma concentrations, and antispastic action of tizanidine (Sirdalud®). J Neurol Neurosurg Psychiatry. 1994;57:1355-1359.
25. Roberts RC, et al. Pharmacokinetics and pharmacodynamics of tizanidine. Neurology. 1994;44(suppl 9):S29-S31.
26. Hoogstraten MC, et al. Tizanidine versus baclofen in the treatment of spasticity in multiple sclerosis patients. Acta Neurol Scand. 1988;77:224-230.
27. Stien R, et al. The treatment of spasticity in multiple sclerosis: A double-blind clinical trial of a new anti-spastic drug tizanidine compared with baclofen. Acta Neurol Scand. 1987;75:190-194.
28. Eyssette M, et al. Multi-centre, double-blind trial of a novel antispastic agent, tizanidine, in spasticity associated with multiple sclerosis. Curr Med Res Opin. 1988;10:699-708.
29. Bass B, et al. Tizanidine versus baclofen in the treatment of spasticity in patients with multiple sclerosis. Can J Neurol Sci. 1988;15(1):15-19.
30. Smith C, et al. Tizanidine treatment of spasticity caused by multiple sclerosis: Results of a double-blind, placebo-controlled trial. Neurology. 1994;44(suppl 9):S34-S43.
31. The United Kingdom Tixanidine Trial Group. A double-blind, placebo-controlled trial of tizanidine in the treatment of spasticity caused by multiple sclerosis. Neurology. 1994;44(suppl 9):S70-S78.
32. Nance PW, et al. Efficacy and safety of tizanidine in the treatment of spasticity in patients with spinal cord injury. Neurology. 1994;44(suppl 9):S44-S52.
33. Lataste X, et al. Comparative profile of tizanidine in the management of spasticity. Neurology. 1994;44(suppl 9):S53-S59.
34. Wallace JD. Summary of combined clinical analysis of controlled clinical trials with tizanidine. Neurology. 1994;44(suppl 9): S60-S69.
35. Denniston PL. Physicians' GenRx 1997. Riverside, CT: Denniston Publishing Inc.; 1996.
36. Luciani A, et al. Sino-atrial and atrio-ventricular node dysfunction in a case of tizanidine overdose. Vet Human Toxicol. 1995; 37:956-497.
37. Ueno K, et al. Phenytoin-tizanidine interaction [letter]. DICP: Annals Pharmacother. 1991;25:1273.